Proteomics International up after signing agreement for diabetic kidney disease test

Proteomics International Laboratories

20/12/2023 02:38

** Shares of Proteomics International Laboratories  PIQ.AX  
 rise as much as 5.7% to A$0.835
    ** The medical technology co signs licence agreement with
U.S.-based Omics Global Solutions
    ** Adds, agreement to expand its PromarkerD's reach in Chile
    ** PromarkerD is a predictive test for diabetic kidney
disease
    ** Licence with Omics Global Solutions for 5 yrs, extendable
by mutual agreement and exclusive to Chile - PIQ
    ** 111,425 shares change hands as of 0226 GMT, vs 30-day
average volume of 59,399 shares
    ** Stock down 16.8% YTD, as of last close

 (Reporting by Roshan Thomas in Bengaluru)
 ((Roshan.Thomas@thomsonreuters.com))